Core Viewpoint - The company received a decision from the Jilin Regulatory Bureau of the China Securities Regulatory Commission regarding issues with the recognition of foreign sales order revenues and internal controls [1] Group 1: Regulatory Actions - The company was ordered to take corrective measures due to imprudent revenue recognition related to foreign sales orders [1] - Warning letters were issued to three individuals: Wang Xueming, Niu Dandan, and Zhang Xingyan [1] Group 2: Internal Control Issues - In 2023, the company recognized revenue from certain foreign sales orders without actual customs declaration and faced situations of product returns [1] - The internal controls related to foreign sales were found to be inadequate, with incomplete documentation for some foreign sales orders [1]

Core Viewpoint - The company is facing short-term challenges in its domestic market due to intensified competition and asset impairment, but it is actively working to stabilize and improve its domestic business while also achieving significant growth in its international operations [1][3][4]. Domestic Market Performance - The company anticipates a significant improvement in cash flow for 2025, projecting a return to positive cash flow compared to the previous year, with net cash flow from operating activities reported at -295 million yuan and -84,300 yuan for 2024 and the first half of 2025, respectively [1][3]. - Efforts to improve cash flow include better collection of accounts receivable, comprehensive cost control, and asset disposals, which will help reduce bad debt risk and enhance liquidity [1][3]. International Market Growth - The company reported overseas revenue of 224 million yuan for the first half of 2025, representing a year-on-year increase of 24.02%, with growth observed in markets such as India, the Philippines, and Turkey [4]. - The company has been actively expanding its international market presence for over 20 years, exporting to more than 120 countries and regions, and has entered a new phase of development characterized by localized management and operations [2][4]. - Recent achievements include winning multiple instrument contracts in India and successfully installing laboratory solutions in Romania, indicating a strong foothold in international markets [5]. Strategic Initiatives - For 2026, the company plans to strengthen its international market position with a "2+2+10" strategy, focusing on deepening its presence in 10 selected countries to enhance its competitive capabilities [6].

证券代码：300396 证券简称：迪瑞医疗 公告编号：2026-005 经查，迪瑞医疗科技股份有限公司（以下简称公司）存在以下问题： 1、公司涉外销售订单收入确认不审慎。公司 2023 年存在部分涉外销售订单 确认收入后，对应商品未实际报关并办理退货情形。上述行为，不符合《企业会 计准则第 14 号——收入(2017)》第五条相关规定，导致公司 2023 年多记营业收 入 369.30 万元，多记营业利润 71.60 万元，违反了《上市公司信息披露管理办 法》（证监会令第 182 号，以下简称《信息披露管理办法》）第三条第一款相关规 定。 2、公司涉外销售内部控制不完善，部分涉外销售订单相关资料保存不完整。 上述情况不符合《企业内部控制基本规范》第十四条、《企业内部控制应用指引 第 9 号——销售业务》第三条、第八条、第十二条有关规定。 迪瑞医疗科技股份有限公司 关于收到中国证券监督管理委员会吉林监管局 行政监管措施决定书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"）于 2026 年 2 月 5 日收到中 ...

Group 1 - The company, Dirui Medical, responded to investor inquiries on its interactive platform, indicating that specific information should be based on the company's disclosed information [2]

Group 1 - The core point of the article is that as of January 31, 2026, the number of shareholders for DiRi Medical is reported to be 15,812 [2]

Core Viewpoint - Recently, Di Rui Medical (300396), part of the China Resources Group's IVD platform, announced a forecast for a net profit loss of between 180 million to 350 million yuan for the fiscal year 2025, marking the first annual loss since its listing 11 years ago [1] Group 1: Financial Performance - The company reported a profit of 15.68 million yuan in Q1 of the previous year, but shifted to a loss of 43.99 million yuan in Q2 and further expanded the loss to 58.94 million yuan in Q3, indicating a continuous deterioration in performance [1] - The expected losses are attributed to intensified market competition, asset impairment, and several operational challenges, particularly in the domestic market [1] - The company experienced a decline in revenue due to underperformance in instrument product reagent output, adjustments in product pricing affecting gross margins, increased marketing expenditures, and higher impairment losses compared to the previous year [1] Group 2: Strategic Adjustments - In response to the challenges, the company is actively adjusting its operational strategies with the support of its controlling shareholder, including management restructuring and marketing strategy adjustments to better align with market changes [2] - The company has significantly improved its cash flow through efforts in receivables collection, expense control, and asset disposals, ensuring sustainable development [2] Group 3: Stock Performance - Di Rui Medical's stock has faced a continuous decline, dropping 44% in 2024 and an additional 20% in 2025, currently valued at only 40% of its historical high in 2023 [2] Group 4: Management Changes - The company underwent a significant board overhaul in August of the previous year, with new appointments indicating a complete takeover by the China Resources Group, as the new chairman, general manager, and deputy general manager all come from the China Resources Pharmaceutical Group [2][3]

"当前，公司国际业务进入到收获期，在聚焦基础医疗基础上实现了海外高端用户突破，今年实现开门 红。"安国柱介绍，迪瑞医疗近期在印度中标多台仪器标段，顺利为罗马尼亚雅西知名连锁实验室Praxis Laboratoarele完成LA-60SE实验室整体解决方案的安装与调试工作，相关设备已投入运行。此外，公司 本地化业务在俄罗斯、印尼、泰国、土耳其等地也将全面开始创收。 根据计划，2026年，迪瑞医疗将重点强化国际市场优势地位。公司在业务辐射120多个国家基础上确定 了"2+2+10"国际战略布局，选取10个国家作为进一步深度孵育的市场，有效夯实重点市场，提升综合 竞争力，促进公司国际业务发展。 转自：中国证券报·中证网 中证报中证网讯（记者 宋维东）迪瑞医疗董事会秘书安国柱1月30日在接受中国证券报记者采访时表 示，受市场竞争加剧、资产减值等因素影响，公司2025年经营面临阶段性挑战，国内市场业务发展在短 期内出现一定波动。公司正多措并举，积极推动国内市场业务企稳向好。同时要看到，公司近年来不断 加大国际市场投入，国际业务发展稳健并进入收获期，有力推动公司向外向型体外诊断企业转型。 迪瑞医疗积极布局海外市场超20年 ...

Core Viewpoint - The company, Dirui Medical (300396), has announced a significant expected loss for the year 2025, projecting a net loss attributable to shareholders between 180 million to 350 million yuan, compared to a profit of 142 million yuan in the previous year [4]. Financial Performance - The expected net profit for 2025 is projected to be a loss of 1.8 billion to 3.5 billion yuan, with a non-recurring net profit loss estimated between 1.85 billion to 3.6 billion yuan, compared to a profit of 1.34 billion yuan in the previous year [4]. - The company's price-to-book ratio (LF) is approximately 1.91 times, and the price-to-sales ratio (TTM) is about 7.1 times based on the latest closing price [4]. Market Challenges - The anticipated shift from profit to loss is attributed to intensified market competition, asset impairment, and several operational challenges, particularly in the domestic market [13]. - Key factors impacting revenue include underperformance in the output of instrument products and reagents, adjustments in product pricing affecting gross margins, increased marketing expenditures, and higher credit and asset impairment losses compared to the previous year [13]. Historical Financial Trends - Historical net profit and non-recurring profit data indicate a downward trend, with the company experiencing a significant decline in profitability from previous years [14]. - The year-on-year growth rates for net profit and non-recurring net profit have shown negative trends, with a notable decrease of 286.72% projected for 2025 [14].

Group 1 - The company, Dirui Medical, announced that its sixth board meeting was held on January 30, 2026, via communication methods [1] - The meeting reviewed the proposal regarding the expected daily related transactions for 2026 [1] Group 2 - The article highlights the development of China's autonomous driving sector, particularly its expansion into Abu Dhabi [1]

一、日常关联交易基本情况 迪瑞医疗科技股份有限公司（以下简称"公司"）于 2026 年 1 月 30 日召开 第六届董事会第六次临时会议，审议通过了《关于 2026 年日常关联交易预计的 议案》。根据日常经营需要，公司及子公司与实际控制人中国华润有限公司（以 下简称"中国华润"）及其控制企业、宁波瑞源生物科技有限公司（以下简称"宁 波瑞源"）、吉林省合众瑞达医学检验所有限公司（以下简称"合众瑞达"）在 销售、采购及租赁方面存在日常关联交易。 证券代码：300396 证券简称：迪瑞医疗 公告编号：2026-003 迪瑞医疗科技股份有限公司 关于 2026 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 中国华润有限公司为公司的实际控制人，董事长郭霆、董事倪冰在中国华润 关联单位任职，在审议上述议案时，应当回避表决。此外，截至 2026 年 1 月， 公司董事兼总经理郎涛及职工代表董事刘康从中国华润关联单位离任时间未满 12 个月，上述人员仍需对上述议案进行回避表决。 该事项已经独立董事专门会议审议通过。 根据《深圳证券交易所创业板股票 ...